REAL-WORLD TREATMENT PATTERNS OF OMALIZUMAB IN CHRONIC IDIOPATHIC/SPONTANEOUS URTICARIA (CIU/CSU) PATIENTS IN THE UNITED STATES

被引：0
|
作者：
Eghrari-Sabet, J.
Sher, E.
Lefebvre, P.
Pilon, D.
Zhdanava, M.
Balp, M.
Kavati, A.
Ortiz, B.
Bernstein, J.
机构：
来源：
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY | 2017年 / 119卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
P162
引用
收藏
页码：S42 / S42
页数：1
相关论文
共 50 条
  • [41] Effect of Anti-IgE (Omalizumab) in chronic idiopathic urticaria (CIU) patients
    Gober, L. M.
    Sterba, P. M.
    Eckman, J. A.
    Saini, S. S.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2008, 121 (02) : S147 - S147
  • [42] ASSURE-CSU: a real-world study of burden of disease in patients with symptomatic chronic spontaneous urticaria
    Weller, Karsten
    Maurer, Marcus
    Grattan, Clive
    Nakonechna, Alla
    Abuzakouk, Mohamed
    Berard, Frederic
    Sussman, Gordon
    Gimenez-Arnau, Ana M.
    de Frutos, Javier Ortiz
    Knulst, Andre
    Canonica, G. Walter
    Hollis, Kelly
    McBride, Doreen
    Balp, Maria-Magdalena
    CLINICAL AND TRANSLATIONAL ALLERGY, 2015, 5
  • [43] Real-world Treatment Patterns Amongst Patients with Chronic Spontaneous Urticaria Initiating Advanced Therapies
    Bernstein, Jonathan
    Thomas, Ryan
    Chuang, Chien-Chia
    Chen, Chao
    Yang, Min
    Martins, Bruno
    Zion, Abigail
    Cyr, Sonya
    Gonzalez, Tayler
    Friedman, Adam
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2025, 155 (02) : AB291 - AB291
  • [44] Omalizumab for the treatment of chronic idiopathic/spontaneous urticaria in children
    Licari, A.
    Castagnoli, R.
    De Filippo, M.
    Mascolo, A.
    Ruffinazzi, G.
    Marseglia, A.
    Leone, M.
    Marseglia, G.
    ALLERGY, 2017, 72 : 322 - 323
  • [45] Commentary: Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria
    Sabroe, R. A.
    BRITISH JOURNAL OF DERMATOLOGY, 2014, 171 (01) : 13 - 15
  • [46] REAL-WORLD HEALTHCARE RESOURCE UTILIZATION IN URTICARIA PATIENTS NEWLY TREATED WITH OMALIZUMAB IN THE UNITED STATES
    Ke, X.
    Kavati, A.
    Wertz, D.
    Huang, Q.
    Wang, L.
    Willey, V. J.
    Stephenson, J. J.
    Ortiz, B.
    Paknis, B.
    Bernstein, J. A.
    Beck, L. A.
    VALUE IN HEALTH, 2017, 20 (05) : A161 - A161
  • [47] Safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria
    Maurer, M.
    Rosen, K.
    Hsieh, H.
    Blogg, M.
    Georgiou, P.
    Braeutigam, M.
    Saini, S.
    ALLERGY, 2012, 67 : 497 - 498
  • [48] Strategies for Discontinuing Omalizumab in Patients with Chronic Urticaria: Real-World Findings
    Seghezzo, Sara
    Tsao, Lulu
    Otani, Iris M.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2019, 143 (02) : AB302 - AB302
  • [49] SUSTAINED IMPROVEMENT IN WORK PRODUCTIVITY AND ACTIVITY IMPAIRMENT IN CHRONIC SPONTANEOUS URTICARIA (CSU) PATIENTS WITH OMALIZUMAB: RESULTS FROM XTEND-CIU
    Maurer, M.
    Rajput, Y.
    Thomas, C.
    Holden, M.
    Yoo, B.
    VALUE IN HEALTH, 2018, 21 : S243 - S243
  • [50] Long-term omalizumab outcomes in chronic idiopathic urticaria: a real-world study
    Kavati, Abhishek
    Zhdanava, Maryia
    Ortiz, Benjamin
    LeCocq, Jason
    Schiffman, Bradd
    Pion, Dominic
    Cheung, Hoi Ching
    Lefebvre, Patrick
    Stone, Brian D.
    ALLERGY AND ASTHMA PROCEEDINGS, 2019, 40 (05) : 321 - 328
12345